October 18, 2018 From zero to hero, Endocyte completes a remarkable transformation The US biotech claims an unexpected victory, scoring a $2.1bn takeover by Novartis on the strength of an asset it had bought for just $12m.
September 11, 2015 Upcoming events: Readouts could mean an IPO for Afferent and a licence for Bavarian
